LB-100抑制蛋白磷酸酶-2A增强胶质母细胞瘤抗肿瘤免疫
该临床前研究在同系胶质瘤模型中评估蛋白磷酸酶2A(PP2A)抑制剂LB-100联合PD1阻断的疗效。C57BL/6小鼠植入GL261-luc或GL261-WT胶质瘤细胞后随机分为对照组、LB-100组、PD1阻断组和联合组。PP2A与PD1双阻断较单药显著改善生存,约25%小鼠肿瘤完全消退,该效应依赖CD4和CD8 T细胞。
要点
- PP2A抑制剂LB-100联合PD1阻断较单药显著改善胶质瘤小鼠生存。
- 联合治疗使约25%小鼠肿瘤完全消退,效应依赖CD4和CD8 T细胞。
- 治愈小鼠建立抗原特异性二次保护性免疫,肿瘤淋巴细胞CD8浸润和效应功能增强。
核心结论
- 这是首个将PP2A抑制与PD1阻断联合用于胶质母细胞瘤的临床前研究,该新型联合方案在动物胶质母细胞瘤模型中提供有效的肿瘤免疫治疗和长期生存。
研究设计与样本
- 临床前研究:C57BL/6小鼠植入鼠源胶质瘤细胞系GL261-luc或GL261-WT,随机分为4个治疗组:对照组、LB-100组、PD1阻断组和联合组。
- 评估生存并详细分析肿瘤浸润白细胞。
主要发现
- PP2A与PD1双阻断较单药治疗显著改善生存。
- 联合治疗使约25%小鼠肿瘤完全消退。
- 该效应依赖CD4和CD8 T细胞,治愈小鼠建立抗原特异性二次保护性免疫。
- 肿瘤淋巴细胞分析显示CD8浸润和效应功能增强。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma (GBM) carries a dismal prognosis despite standard multimodal treatment with surgery, chemotherapy and radiation. Immune checkpoint inhibitors, such as PD1 blockade, for treatment of GBM failed to show clinical benefit. Rational combination strategies to overcome resistance of GBM to checkpoint monotherapy are needed to extend the promise of immunotherapy to GBM management. Emerging evidence suggests that protein phosphatase 2A (PP2A) plays a critical role in the signal transduction pathways of both adaptive and innate immune cells and that inhibition of PP2A could enhance cancer immunity. We investigated the use of a PP2A inhibitor, LB-100, to enhance antitumor efficacy of PD1 blockade in a syngeneic glioma model. METHODS: C57BL/6 mice were implanted with murine glioma cell line GL261-luc or GL261-WT and randomized into 4 treatment arms: (i) control, (ii) LB-100, (iii) PD1 blockade and (iv) combination. Survival was assessed and detailed profiling of tumor infiltrating leukocytes was performed. RESULTS: Dual PP2A and PD1 blockade significantly improved survival compared with monotherapy alone. Combination therapy resulted in complete regression of tumors in about 25% of mice. This effect was dependent on CD4 and CD8 T cells and cured mice established antigen-specific secondary protective immunity. Analysis of tumor lymphocytes demonstrated enhanced CD8 infiltration and effector function. CONCLUSION: This is the first preclinical investigation of the effect of combining PP2A inhibition with PD1 blockade for GBM. This novel combination provided effective tumor immunotherapy and long-term survival in our animal GBM model.
引用
- Maggio D, Ho WS, Breese R, et al. Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma. J Neurooncol. 2020. PMID: 32342332. doi:10.1007/s11060-020-03517-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。